Strawn Jeffrey R, Patel Nick C, Chu Wen-Jang, Lee Jing-Huei, Adler Caleb M, Kim Mi Jung, Bryan Holly S, Alfieri David C, Welge Jeffrey A, Blom Thomas J, Nandagopal Jayasree J, Strakowski Stephen M, DelBello Melissa P
University of Cincinnati, College of Medicine, Cincinnati, OH 45267, USA.
J Am Acad Child Adolesc Psychiatry. 2012 Jun;51(6):642-51. doi: 10.1016/j.jaac.2012.03.009. Epub 2012 May 5.
This study used proton magnetic resonance spectroscopy ((1)H MRS) to evaluate the in vivo effects of extended-release divalproex sodium on the glutamatergic system in adolescents with bipolar disorder, and to identify baseline neurochemical predictors of clinical remission.
Adolescents with bipolar disorder who were experiencing a manic or mixed episode (N = 25) were treated with open-label, extended-release divalproex (serum levels 85-125 μg/mL) and underwent (1)H MRS scanning at baseline (before treatment) and on days 7 and 28. Healthy comparison subjects (n = 15) also underwent (1)H MRS scanning at the same time points. Glutamate (Glu) and glutamate+glutamine (Glx) concentrations were measured in three voxels: anterior cingulate cortex (ACC), left ventrolateral prefrontal cortex (LVLPFC), and right ventrolateral prefrontal cortex (RVLPFC), and were compared between bipolar and healthy subjects. Within the bipolar subjects, Glu and Glx concentrations at baseline and each time point were also compared between remitters and nonremitters after divalproex treatment.
At baseline, no differences in Glu or Glx concentrations between bipolar and healthy subjects were observed. Group (HC vs. BP) by time effects revealed an interaction for Glu in the ACC, and change over time effects for Glx were noted in the ACC in patients with bipolar disorder (increase from day 0 to day 7 and then a decrease from day 7 to day 28) but not in HC. Remitters had significantly lower baseline Glx concentrations in LVLPFC, and in remitters the change in LVLPFC Glu correlated with the change in YMRS score.
Successful treatment of mania with divalproex may be predicted by lower baseline concentrations of Glx in the LVLPFC. In addition, in remitters, the degree of symptomatic improvement is related to the change in Glu concentrations in this region, suggesting that divalproex may work via modulation of the prefrontal glutamatergic system in youth with bipolar disorder.
本研究采用质子磁共振波谱(¹H MRS)来评估缓释丙戊酸二钠对双相情感障碍青少年谷氨酸能系统的体内效应,并确定临床缓解的基线神经化学预测指标。
处于躁狂或混合发作期的双相情感障碍青少年(N = 25)接受开放标签的缓释丙戊酸治疗(血清水平85 - 125μg/mL),并在基线(治疗前)、第7天和第28天接受¹H MRS扫描。健康对照受试者(n = 15)也在相同时间点接受¹H MRS扫描。在三个体素中测量谷氨酸(Glu)和谷氨酸 + 谷氨酰胺(Glx)浓度:前扣带回皮质(ACC)、左侧腹外侧前额叶皮质(LVLPFC)和右侧腹外侧前额叶皮质(RVLPFC),并在双相情感障碍患者和健康受试者之间进行比较。在双相情感障碍受试者中,还比较了丙戊酸治疗后缓解者和未缓解者在基线及每个时间点的Glu和Glx浓度。
在基线时,未观察到双相情感障碍患者和健康受试者之间Glu或Glx浓度的差异。组(健康对照与双相情感障碍)×时间效应显示ACC中Glu存在交互作用,双相情感障碍患者的ACC中Glx随时间有变化效应(从第0天到第7天增加,然后从第7天到第28天下降),而健康对照受试者中未观察到。缓解者LVLPFC中的基线Glx浓度显著较低,并且在缓解者中,LVLPFC中Glu的变化与Young躁狂量表(YMRS)评分的变化相关。
LVLPFC中较低的基线Glx浓度可能预测丙戊酸成功治疗躁狂。此外,在缓解者中,症状改善程度与该区域Glu浓度的变化有关,这表明丙戊酸可能通过调节双相情感障碍青少年的前额叶谷氨酸能系统发挥作用。